HUP0301697A2 - Orálisan adagolható vakcinakészítmény - Google Patents
Orálisan adagolható vakcinakészítményInfo
- Publication number
- HUP0301697A2 HUP0301697A2 HU0301697A HUP0301697A HUP0301697A2 HU P0301697 A2 HUP0301697 A2 HU P0301697A2 HU 0301697 A HU0301697 A HU 0301697A HU P0301697 A HUP0301697 A HU P0301697A HU P0301697 A2 HUP0301697 A2 HU P0301697A2
- Authority
- HU
- Hungary
- Prior art keywords
- vaccine
- antigens
- preparation
- oral solid
- solid dose
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 7
- 239000007787 solid Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 238000002360 preparation method Methods 0.000 abstract 3
- 239000000654 additive Substances 0.000 abstract 2
- 210000000214 mouth Anatomy 0.000 abstract 2
- 244000052769 pathogen Species 0.000 abstract 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229940069428 antacid Drugs 0.000 abstract 1
- 239000003159 antacid agent Substances 0.000 abstract 1
- 230000001458 anti-acid effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 238000000859 sublimation Methods 0.000 abstract 1
- 230000008022 sublimation Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
A jelen találmány tárgya új, orálisan alkalmazható vakcinakészítmény.A találmány szerinti vakcina szilárd halmazállapotú, antigénből ésmegfelelő adalékokból álló készítmény, mely a szájba juttatva gyorsanfeloldódik a nyálban, és ezáltal a szájüregbe bocsátja a benne lévőhatóanyagot. Közelebbről, a szilárd halmazállapotú készítményvakcinamassza lehet, mely folyékony halmazállapotú közegből, ígypéldául oldatból vagy szuszpenzióból szublimálással, előnyösenfagyasztva szárítással végzett szublimálással állítható elő. Atalálmány szerinti vakcina előnyösen a szervezetet a nyálkahártyánkeresztül megfertőző vagy elözönlő kórokozók antigénjeit vagy ezekszármazékait tartalmazza, valamint ezeken kívül valamely savkötőhatású adalékot. Különösen előnyös az olyan vakcina, amely kombináltkészítmény, így több antigént tartalmaz, és még előnyösebb az olyanvakcina, amely több kórokozó antigénjeit tartalmazza. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0020089.9A GB0020089D0 (en) | 2000-08-15 | 2000-08-15 | Vaccine Composition |
PCT/IB2001/001711 WO2002013858A1 (en) | 2000-08-15 | 2001-08-14 | Oral solid dose vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0301697A2 true HUP0301697A2 (hu) | 2003-08-28 |
HUP0301697A3 HUP0301697A3 (en) | 2004-11-29 |
Family
ID=9897656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0301697A HUP0301697A3 (en) | 2000-08-15 | 2001-08-14 | Oral solid dose vaccine |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040013695A1 (hu) |
EP (1) | EP1309344A1 (hu) |
JP (1) | JP2004506020A (hu) |
KR (1) | KR20030031978A (hu) |
CN (1) | CN1842345A (hu) |
AU (2) | AU8616801A (hu) |
BR (1) | BR0113301A (hu) |
CA (1) | CA2424160A1 (hu) |
GB (1) | GB0020089D0 (hu) |
HU (1) | HUP0301697A3 (hu) |
IL (1) | IL154404A0 (hu) |
MX (1) | MXPA03001392A (hu) |
NO (1) | NO20030713L (hu) |
NZ (1) | NZ524164A (hu) |
PL (1) | PL362481A1 (hu) |
WO (1) | WO2002013858A1 (hu) |
ZA (1) | ZA200301210B (hu) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0000891D0 (en) * | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
US20050118137A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20040247565A1 (en) * | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20050201981A1 (en) * | 2004-03-10 | 2005-09-15 | Chih-Ping Liu | Method of optimizing treatment with interferon-tau |
US20050118138A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20050084478A1 (en) * | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
DK2116257T3 (da) | 2000-08-09 | 2013-02-04 | Alk Abello As | Parenterale vaccineformuleringer og anvendelser deraf |
IL162857A0 (en) * | 2002-01-15 | 2005-11-20 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Oral vaccination |
DE10224086A1 (de) * | 2002-05-31 | 2003-12-11 | Bayer Ag | Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker |
MXPA05005528A (es) | 2002-11-26 | 2006-04-05 | Alk Abello As | Producto farmaceutico de alergeno. |
AU2004216559B2 (en) | 2003-02-28 | 2010-05-27 | Alk-Abello A/S | Dosage form having a saccharide matrix |
US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
NZ627167A (en) | 2003-10-16 | 2015-10-30 | Stephen John Ralph | Immunomodulating compositions and uses therefor |
US20080025948A1 (en) * | 2004-03-10 | 2008-01-31 | Chih-Ping Liu | Methods of Treatment Using Interferon-Tau |
US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
US20060115499A1 (en) * | 2004-09-27 | 2006-06-01 | Alk-Abello A/S | Liquid allergy vaccine formulation for oromucosal administration |
US20090155351A1 (en) | 2005-10-04 | 2009-06-18 | Alk-Abello A/S | Solid Vaccine Formulation |
EP1854478A1 (en) * | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
DK2187926T3 (da) | 2007-09-11 | 2012-04-02 | Univ Koebenhavn | Forebyggelse af diabetes ved administration af gliadin |
GB201009273D0 (en) * | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
FR2960781B1 (fr) * | 2010-06-07 | 2013-11-22 | Sanofi Pasteur | Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue |
ES2602506T3 (es) * | 2010-10-08 | 2017-02-21 | R.P. Scherer Technologies, Llc | Forma de dosificación de disolución rápida de una vacuna oral usando almidón |
TW201233803A (en) | 2010-12-02 | 2012-08-16 | Oncolytics Biotech Inc | Lyophilized viral formulations |
AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
WO2012103472A1 (en) * | 2011-01-28 | 2012-08-02 | Brian Pulliam | Granularized particular thermostable rotovirus vaccine preparation |
KR102108876B1 (ko) * | 2012-03-05 | 2020-05-12 | 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 베이웨이에스, 미니스테리 반 폭스겐트존하이트, 벨지인 엔 스포츠 | 건조된 생물학적 물질을 안정화시키는 방법 및 조성물 |
WO2015013549A1 (en) * | 2013-07-25 | 2015-01-29 | Invado Pharmaceuticals, LLC | Treating oral inflammation, injury or pain |
AU2014373928C1 (en) * | 2013-12-31 | 2020-12-17 | Access To Advanced Health Institute | Single vial vaccine formulations |
EP2952200A1 (en) | 2014-06-04 | 2015-12-09 | Alk-Abelló A/S | Allergen for prophylactic treatment of allergy |
JP6916113B2 (ja) * | 2015-11-27 | 2021-08-11 | 日東電工株式会社 | 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法 |
EP3381468A4 (en) * | 2015-11-27 | 2019-06-05 | Nitto Denko Corporation | DRIED INFLUENZA VACCINE PREPARATION AND METHOD FOR PRODUCING A DRIED INFLUENZED VACCINE PREPARATION |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US4636385A (en) * | 1985-02-15 | 1987-01-13 | The Wistar Institute Of Anatomy & Biology | Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection |
GB9722682D0 (en) * | 1997-10-27 | 1997-12-24 | Scherer Ltd R P | Pharmaceutical products |
DE60028390T2 (de) * | 1999-08-17 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff |
KR100366608B1 (ko) * | 2000-02-15 | 2003-01-09 | 마스터진(주) | 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신 |
-
2000
- 2000-08-15 GB GBGB0020089.9A patent/GB0020089D0/en not_active Ceased
-
2001
- 2001-08-14 EP EP01965535A patent/EP1309344A1/en not_active Withdrawn
- 2001-08-14 JP JP2002518997A patent/JP2004506020A/ja active Pending
- 2001-08-14 US US10/344,798 patent/US20040013695A1/en not_active Abandoned
- 2001-08-14 WO PCT/IB2001/001711 patent/WO2002013858A1/en not_active Application Discontinuation
- 2001-08-14 NZ NZ524164A patent/NZ524164A/en unknown
- 2001-08-14 KR KR10-2003-7002236A patent/KR20030031978A/ko not_active Application Discontinuation
- 2001-08-14 HU HU0301697A patent/HUP0301697A3/hu unknown
- 2001-08-14 CN CNA018173926A patent/CN1842345A/zh active Pending
- 2001-08-14 AU AU8616801A patent/AU8616801A/xx active Pending
- 2001-08-14 AU AU2001286168A patent/AU2001286168B2/en not_active Ceased
- 2001-08-14 CA CA002424160A patent/CA2424160A1/en not_active Abandoned
- 2001-08-14 PL PL01362481A patent/PL362481A1/xx unknown
- 2001-08-14 BR BR0113301-2A patent/BR0113301A/pt not_active IP Right Cessation
- 2001-08-14 IL IL15440401A patent/IL154404A0/xx unknown
- 2001-08-14 MX MXPA03001392A patent/MXPA03001392A/es unknown
-
2003
- 2003-02-13 ZA ZA200301210A patent/ZA200301210B/en unknown
- 2003-02-14 NO NO20030713A patent/NO20030713L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20030713D0 (no) | 2003-02-14 |
NO20030713L (no) | 2003-04-11 |
ZA200301210B (en) | 2004-03-12 |
GB0020089D0 (en) | 2000-10-04 |
AU2001286168B2 (en) | 2004-09-23 |
IL154404A0 (en) | 2003-09-17 |
US20040013695A1 (en) | 2004-01-22 |
CN1842345A (zh) | 2006-10-04 |
JP2004506020A (ja) | 2004-02-26 |
KR20030031978A (ko) | 2003-04-23 |
MXPA03001392A (es) | 2004-12-13 |
EP1309344A1 (en) | 2003-05-14 |
PL362481A1 (en) | 2004-11-02 |
CA2424160A1 (en) | 2002-02-21 |
BR0113301A (pt) | 2003-07-15 |
HUP0301697A3 (en) | 2004-11-29 |
AU8616801A (en) | 2002-02-25 |
WO2002013858A1 (en) | 2002-02-21 |
NZ524164A (en) | 2004-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0301697A2 (hu) | Orálisan adagolható vakcinakészítmény | |
HUP0201877A2 (hu) | Hal zselatint tartalmazó, gyorsan diszpergálódó dózis formák | |
HUP0203056A1 (hu) | Vakcinakészítmény | |
HUP0401314A2 (hu) | Leheletfrissítő film | |
HUP0203168A2 (hu) | Készítmények nyálkahártyán át történő beadásra | |
HUP0301394A2 (hu) | Eljárások és készítmény orális vakcinációra | |
DK1435909T3 (da) | Stabil sammensætning indeholdende partikler i en frossen vandig matrix | |
MEP49308A (en) | Once-a-day oxycodone formulations | |
HUP0301868A2 (hu) | Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz | |
ATE348601T1 (de) | Im munde zerfallende tablette enthaltend ein benzimidazole | |
HUP0202846A2 (hu) | Intranazális influenzavírus-oltóanyag | |
JP2005503322A5 (hu) | ||
HUP0302643A2 (hu) | Vakcina | |
HUP0301851A2 (hu) | Javított diszpergálhatóságú szárazpor-összetételek | |
HUP0203204A2 (hu) | Orális adagolási forma | |
ATE295180T1 (de) | Zubereitung zur immunisierung gegen den aids- virus | |
HUP0001089A2 (hu) | Gyógyászati készítmények férfiak erekciós zavarainak kezelésére | |
HUP0303182A2 (hu) | Gyógyászati készítmények | |
HUP0301349A2 (hu) | IL-11-tartalmú készítmények | |
BRPI0501101A (pt) | Dispositivo de cabeçote de fio dental com um meio de administração de agente de sabor | |
HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
HUP0102365A2 (hu) | Lipofil glükokortikoszteroidot és csak egy felületaktív anyagot tartalmazó micellákból álló gyógyszerkészítmények, valamint eljárás előállításukra | |
HUP0401592A2 (hu) | Modafinilvegyület és ciklodextrin keverékek, eljárás az előállításukra és ezeket tartalmazó készítmények | |
HUP0402492A2 (hu) | 5HT4 részleges agonistát tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |